{"id":174319,"date":"2026-09-25T19:18:11","date_gmt":"2026-09-25T19:18:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/174319\/"},"modified":"2026-09-25T19:18:11","modified_gmt":"2026-09-25T19:18:11","slug":"novo-nordisk-licenses-nanexa-drug-delivery-technology-in-deal-worth-up-to-e1-17-billion","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/174319\/","title":{"rendered":"Novo Nordisk Licenses Nanexa Drug-Delivery Technology in Deal Worth Up to \u20ac1.17 Billion"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk (NYSE:NVO) has agreed to license drug-delivery technology from Swedish biotechnology company Nanexa in an agreement potentially worth up to \u20ac1.165 billion.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The exclusive global licensing agreement covers Nanexa&#8217;s PharmaShell platform and up to five development programmes targeting obesity, type 2 diabetes and other cardiometabolic conditions.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The technology could potentially allow treatments that are currently administered weekly to be delivered on a monthly or quarterly schedule, although development and regulatory work will be required before any such products could reach the market.  <\/p>\n<p>        Nanexa Eligible for Up to \u20ac1.165 Billion in Payments          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Under the agreement, Novo Nordisk will pay a total of \u20ac615 million comprising upfront payments and potential development and regulatory milestone payments.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Additional payments are linked to sales milestones, taking the potential total value of the agreement to \u20ac1.165 billion.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Nanexa is also eligible to receive royalties in the low-single-digit percentage range on global net sales of products developed under the agreement.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The milestone and royalty payments will depend on the progress and commercial performance of the relevant development programmes.  <\/p>\n<p>        Novo Nordisk to Lead Development and Commercialisation          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk will be responsible for the global development and commercialisation of products covered by the agreement.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The programmes will focus on obesity, type 2 diabetes and other cardiometabolic conditions, incorporating Nanexa&#8217;s PharmaShell drug-delivery platform.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The agreement was announced after the market closed on Thursday.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk stock price  <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (NYSE:NVO) has agreed to license drug-delivery technology from Swedish biotechnology company Nanexa in an agreement potentially&hellip;\n","protected":false},"author":2,"featured_media":174320,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[80110,80007,78058,80111,272,26615],"class_list":["post-174319","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-drug-delivery-technology","tag-global-development","tag-licensing-agreement","tag-nanexa","tag-novo-nordisk","tag-potential-development"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117333295286555737","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/174319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=174319"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/174319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/174320"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=174319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=174319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=174319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}